Singapore, 11 March 2025 – Hyphens Pharma International Limited, Singapore’s leading specialty pharmaceutical group, has entered into an exclusive agreement with Germany’s medac GmbH to commercialize the Metoject® subcutaneous auto-injector pen in Singapore, Malaysia, the Philippines, and Vietnam. This strategic partnership expands treatment options for rheumatoid arthritis and plaque psoriasis patients across Southeast Asia.
Innovative Treatment Solution for Chronic Conditions
Metoject® delivers methotrexate, a first-line treatment for rheumatoid arthritis recognized by both European and American medical guidelines. The auto-injector pen offers significant advantages over oral administration, including more consistent bioavailability and reduced gastrointestinal side effects. Its user-friendly design features a two-step injection process with built-in needle protection, available in multiple dosages (7.5mg, 10mg, and 15mg) to accommodate individualized treatment plans.
Addressing Growing Regional Healthcare Needs
With an estimated 525,000 rheumatoid arthritis patients in Southeast Asia, this partnership addresses a critical treatment gap in the region. Mr. Lim See Wah, Chairman and CEO of Hyphens Pharma, emphasized the significance of this collaboration: “Metoject® represents an important addition to our specialty pharma portfolio, aligning with our mission to bring innovative, patient-centric solutions to ASEAN markets. We’re particularly pleased to offer healthcare providers an effective subcutaneous alternative that can improve treatment outcomes.”
Proven Global Track Record
The Metoject® auto-injector has already been successfully commercialized in over 15 countries across Europe, the United States, and Japan. Mr. Frank Lucaßen, CEO of medac, noted: “We selected Hyphens Pharma as our regional partner based on their exceptional regulatory expertise and established distribution network. Their deep understanding of Southeast Asian markets makes them the ideal collaborator to introduce this important therapy.”
Strategic Expansion of Specialty Portfolio
This agreement strengthens Hyphens Pharma’s position as a leader in specialty pharmaceuticals while expanding its rheumatology offerings. The company anticipates launching Metoject® in the four target markets following regulatory approvals, with the product expected to benefit both rheumatologists and dermatologists treating plaque psoriasis.
–
Medac GmbH is a German pharmaceutical company specializing in rheumatology, urology, hematology and oncology treatments, with products available in more than 90 countries worldwide.
About Hyphens Pharma International Limited
Hyphens Pharma International Limited is Singapore’s premier specialty pharmaceutical and consumer healthcare group with direct operations in five ASEAN countries and distribution networks across 14 additional markets.
